Lymphoma, Mantle-Cell
-
Subject Areas on Research
- A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform.
- B-cell lymphoma with hyaline vascular Castleman disease-like features: a clinicopathologic study.
- Bilateral panocular involvement with mantle-cell lymphoma.
- CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course.
- Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With Secondary Acquisition of t(11;14)(q13;q32)/CCND1-IGH: A Rare Variant Of Richter Transformation to Mantle Cell Lymphoma.
- Chronic lymphocytic leukemia with t(6;14) (p21;q32) CCND3-IGH: CCND3 rearrangement does not necessarily define a cyclin D1-negative mantle cell lymphoma.
- Clonally related composite follicular lymphoma and mantle cell lymphoma with clinicopathologic features and biological implications.
- Composite mantle cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: a clinicopathologic and molecular study.
- Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling.
- Dose-intense chemoimmunotherapy plus radioimmunotherapy in high-risk diffuse large B-cell lymphoma and mantle cell lymphoma: a phase II study.
- EZH2 expression is associated with inferior overall survival in mantle cell lymphoma.
- Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial.
- Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909.
- Inhibition of the p53 E3 ligase HDM-2 induces apoptosis and DNA damage--independent p53 phosphorylation in mantle cell lymphoma.
- Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms.
- Ki67 and PIM1 expression predict outcome in mantle cell lymphoma treated with high dose therapy, stem cell transplantation and rituximab: a Cancer and Leukemia Group B 59909 correlative science study.
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
- Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphoma.
- Mantle Cell Lymphoma Involving Skin: A Clinicopathologic Study of 37 Cases.
- Mantle Cell Lymphoma With MYC Rearrangement: A Report of 17 Patients.
- Mantle Cell Lymphoma With Mantle Zone Growth Pattern.
- Mantle cell lymphoma with plasma cell differentiation.
- Molecular characteristics of mantle cell lymphoma presenting with clonal plasma cell component.
- Multifocal mantle cell lymphoma in situ in the setting of a composite lymphoma.
- Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.
- Overcoming drug resistance in mantle cell lymphoma using a combination of dose-dense and intense therapy.
- Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling.
- Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.
- Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
- SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.
- Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials.
- Sequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphoma.
- Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
- Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimen.
- Systemic interleukin-2 and adoptive transfer of lymphokine-activated killer cells improves antibody-dependent cellular cytotoxicity in patients with relapsed B-cell lymphoma treated with rituximab.
- The biology of human lymphoid malignancies revealed by gene expression profiling.
- The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells.
- Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501).
- Updated survival analysis of two sequential prospective trials of R-MACLO-IVAM followed by maintenance for newly diagnosed mantle cell lymphoma.
- Use of tissue microarray and automated quantitative analysis for screening and validation of potential biomarkers in mantle cell lymphoma.
- Value of CD23 determination by flow cytometry in differentiating mantle cell lymphoma from chronic lymphocytic leukemia/small lymphocytic lymphoma.
-
Keywords of People
- Stefanovic, Alexandra, Associate Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy